FDA Approved Cobenfy: Non-Dopaminergic Treatment for Schizophrenia
In a significant development for the treatment of schizophrenia, the FDA has recently approved Cobenfy, a novel medication that targets schizophrenia through non-dopaminergic pathways. This approval marks a shift from traditional antipsychotic medications, which primarily focus on dopamine modulation, and introduces new hope for patients who may not have responded well to conventional treatments or have experienced debilitating side effects.
Cobenfy is a combination of two drugs: xanomeline and trospium chloride.
- Xanomeline, a muscarinic receptor agonist, targets the cholinergic system in the brain, which is believed to play a crucial role in the symptoms of schizophrenia.
- Trospium chloride, on the other hand, is a muscarinic receptor antagonist that does not cross the blood-brain barrier, mitigating the peripheral side effects of xanomeline without diminishing its central therapeutic effects.
WATCH YOUTUBE VIDEO FOR DETAILS:
In this video, Dr. Harvinder Singh has discussed this new medication in the following sections:
- Mechanism of Action: How is this different from other antipsychotics
- How to Dose and What to check Before Dosing?
- Contraindications & Cautions.
- Common Side Effects
- Can this cause EPS, Weight Gain & QTc Prolongation?
- Drug Interactions
Below is one slide from this presentation:
HOW TO DOSE?
FOR ACADEMY MEMBERS:
Xanomeline-Trospium for Schizophrenia
This chapter is summarized in the following sections:
- Mechanism of Action: how is this different from other antipsychotics?
- Dosing: How to Dose & Titrate?
- Effectiveness: is this effective for both positive and negative symptoms of schizophrenia?
- Response Time: How early is the response seen with KarXT?
- Common side effects
- What is the risk of EPS, Weight Gain and Somnolence?
- Contraindications & Cautions
- Results from EMERGENT-3 trial (Phase 3 Double-blind, Randomized, Placebo-controlled trial): published in JAMA Psychiatry on May 1, 2024.
INTERESTED IN ACCESS TO THIS & OTHER CLINICALLY RELEVANT LECTURE SERIES?
JOIN ACADEMY MEMBERSHIP:
This is a closed membership for medical professionals only.
- 400+ Clinically Relevant Chapters: Each chapter within these sections is of direct clinical relevance for your daily practice. (Table of Content)
- Journal Club: we will post the most recently published psychiatry articles relevant to your daily clinical practice. (Read Content)
- Clinical Case Discussion: Dr. Singh (Psychiatry) and Dr. Kaur (Family Medicine) discuss clinical cases to integrate the clinical cases from Psychiatry and Medicine. (Read Content)
- Discussion Forum & Community: Connect with other medical professionals and discuss your difficult-to-treat clinical cases. (Academy Network)
- Goal: is to have all important clinically relevant topics in one place for ease of access.
DISCOUNTS AVAILABLE FOR: Residents & Students ONLY.
Email us your student information (program information and way to confirm your student status) to: HSingh@PsychiatryEducationForum.com
© 2024 All Rights Reserved.
Responses